AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23520456 — intervention group
Group type: COMPARATOR
Intervention: Lower completed level of schooling (control group)
Number of subjects: 986
Study 21677052 — intervention group
Group type: EXPERIMENTAL
Intervention: High fructose (HF) - 80 g fructose/d
Number of subjects: 29
Study 21677052 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose (HS) - 80 g sucrose/d
Number of subjects: 29
Study 21677052 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fructose (MF) - 40 g fructose/d
Number of subjects: 29
Study 21677052 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium glucose (MG) - 40 g glucose/d
Number of subjects: 29
Study 21677052 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose (HG) - 80 g glucose/d
Number of subjects: 29
Study 21677052 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice to consume low amounts of fructose
Number of subjects: 29
Study 19434759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of bronchial arterial infusion (BAI) and rAd‐p53
Number of subjects: 58
Study 19434759 — intervention group
Group type: COMPARATOR
Intervention: Control group (only BAI)
Number of subjects: 58
Study 16425970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine Sandoz retard 30 after high-fat American breakfast
Number of subjects: 28
Study 16425970 — intervention group
Group type: COMPARATOR
Intervention: Adalat OROS 30 after high-fat American breakfast
Number of subjects: 28
Study 16425970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine Sandoz retard 30 after fasting
Number of subjects: 28
Study 16425970 — intervention group
Group type: COMPARATOR
Intervention: Adalat OROS 30 after fasting
Number of subjects: 28
Study 14747675 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas
Number of subjects: 12
Study 14747675 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas plus Na(2)EDTA at a ratio of 1:2 mol/mol
Number of subjects: 12
Study 11349181 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain
Number of subjects: 483
Study 10966700 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mL/kg
Number of subjects: 221
Study 10966700 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mL/kg
Number of subjects: 221
Study 10966700 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL/kg
Number of subjects: 221
Study 10966700 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of 100 mL
Number of subjects: 221
Study 8990639 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet retention
Number of subjects: 25
Study 8990639 — intervention group
Group type: COMPARATOR
Intervention: Stud retention
Number of subjects: 25
Study 1620810 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered coffee (6 cups/day)
Number of subjects: 64
Study 1620810 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled coffee (6 cups/day)
Number of subjects: 64
Study 1620810 — intervention group
Group type: COMPARATOR
Intervention: No coffee (abstinence from caffeine)
Number of subjects: 64
Study 6370975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine (100‐200 mg/day)
Number of subjects: 0
Study 6370975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30372761 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive stimulus selection algorithm
Number of subjects: 0
Study 30372761 — intervention group
Group type: COMPARATOR
Intervention: Random stimulus selection
Number of subjects: 0
Study 27587557 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone application for patients and monitoring website for physiotherapists)
Number of subjects: 157
Study 27587557 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 27587557 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 157
Study 24760382 — intervention group
Group type: COMPARATOR
Intervention: Micronutrients supplementation for 6 months
Number of subjects: 127
Study 24760382 — intervention group
Group type: COMPARATOR
Intervention: Probiotics supplementation for 3 months
Number of subjects: 127
Study 24760382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 127
Study 23216674 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a, 44 μg subcutaneously three times weekly (tiw)
Number of subjects: 129
Study 23216674 — intervention group
Group type: COMPARATOR
Intervention: IFNβ‐1b, 250 μg subcutaneously every other day
Number of subjects: 129
Study 23216674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 129
Study 19591987 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid with higher estradiol concentrations
Number of subjects: 0
Study 19591987 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid with higher testosterone concentrations
Number of subjects: 0
Study 19591987 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid with higher progesterone concentrations
Number of subjects: 0
Study 18070305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt training (daily sessions for three months)
Number of subjects: 46
Study 18070305 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 46
Study 18070305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt training
Number of subjects: 46
Study 16250265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy for 12 weeks
Number of subjects: 0
Study 12020980 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering fibrate (gemfibrozil 600 mg orally twice daily for 3 months, then combined with HRT for 6 months)
Number of subjects: 0
Study 12020980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (2 mg oestradiol + 1 mg norethisterone acetate once daily for 3 months, then combined with gemfibrozil for 6 months)
Number of subjects: 0
Study 10541127 — intervention group
Group type: EXPERIMENTAL
Intervention: Valved PICC
Number of subjects: 362
Study 10541127 — intervention group
Group type: COMPARATOR
Intervention: Clamped PICC
Number of subjects: 362
Study 8998395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 20 mg/day (titrated up to 60 mg/day)
Number of subjects: 163
Study 8998395 — intervention group
Group type: COMPARATOR
Intervention: Doxepin 75 mg/day (titrated up to 300 mg/day)
Number of subjects: 163
Study 2223891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 50
Study 2223891 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 50
Study 31451252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention (NI) - EPA-enriched nutrition supplement (2 bottles/day, 550 kcal/day) during NACRT
Number of subjects: 62
Study 31451252 — intervention group
Group type: COMPARATOR
Intervention: Normal Diet (ND)
Number of subjects: 62
Study 30379936 — intervention group
Group type: COMPARATOR
Intervention: Standard dose pioglitazone (15 mg/day)
Number of subjects: 75
Study 30379936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pioglitazone (7.5 mg/day)
Number of subjects: 75
Study 26874974 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)/time to progression (TTP)
Number of subjects: 8617
Study 26874974 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective response rate (ORR)
Number of subjects: 8617
Study 26874974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard ratios (HRs) of PFS/TTP
Number of subjects: 8617
Study 26874974 — intervention group
Group type: EXPERIMENTAL
Intervention: PFS/OS correlation for HER2-positive MBC patients
Number of subjects: 8617
Study 24182347 — intervention group
Group type: EXPERIMENTAL
Intervention: sPD-1 concentrations in early RA (median 0.421 ng/mL, IQR 0.04-2.560 ng/mL)
Number of subjects: 34
Study 24182347 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in sPD-1
Number of subjects: 34
Study 24182347 — intervention group
Group type: EXPERIMENTAL
Intervention: sPD-1 concentration
Number of subjects: 34
Study 22373720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4463
Study 22373720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4463
Study 20560112 — intervention group
Group type: EXPERIMENTAL
Intervention: Immulina® (400 mg/day) for seven days
Number of subjects: 21
Study 20560112 — intervention group
Group type: COMPARATOR
Intervention: Immulina® (200 mg/day) for seven days
Number of subjects: 21
Study 20560112 — intervention group
Group type: EXPERIMENTAL
Intervention: Immulina® (200 mg and 400 mg per day) for seven days
Number of subjects: 21
Study 18572352 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Vascular Talent Thoracic Stent Graft System
Number of subjects: 195
Study 18572352 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (retrospective control)
Number of subjects: 195
Study 15653019 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventional strategy (IS)
Number of subjects: 1810
Study 15653019 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (CS)
Number of subjects: 1810
Study 12451305 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on two legs with the eyes open
Number of subjects: 100
Study 12451305 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on two legs with the eyes closed
Number of subjects: 100
Study 10470387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P50: propofol 1% 10 ml/thiopentone 2.5% 10 ml
Number of subjects: 90
Study 10470387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P75: propofol 1% 15 ml/thiopentone 2.5% 5 ml
Number of subjects: 90
Study 10470387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P100: propofol 1% 20 ml/lignocaine 1% 4 ml
Number of subjects: 90
Study 10470387 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 2.5% (control group)
Number of subjects: 90
Study 10470387 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/thiopentone admixture
Number of subjects: 90
Study 9156906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (optimal dose)
Number of subjects: 0
Study 9156906 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler color ultrasonography
Number of subjects: 0
Study 1862227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of intramniotic prostaglandin (PG) F2a injection and intracervical laminaria tents (group A, 50 women)
Number of subjects: 128
Study 1862227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramniotic PGF2a injection only (group B, 51 women)
Number of subjects: 128
Study 1862227 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria tents followed by intracervical PGF2a tablets insertion (group C, 27 women)
Number of subjects: 128
Study 7091604 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 100
Study 7091604 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular papaveretum
Number of subjects: 100
Study 31982477 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Vitamin C claim
Number of subjects: 3815
Study 31982477 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning
Number of subjects: 3815
Study 31982477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit image
Number of subjects: 3815
Study 31982477 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Vitamin C claim without health warning
Number of subjects: 3815
Study 31274187 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneal approach (PRA)
Number of subjects: 77
Study 31274187 — intervention group
Group type: COMPARATOR
Intervention: Lateral transperitoneal approach (LTA)
Number of subjects: 77
Study 31274187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone-producing adenoma (PRA)
Number of subjects: 77
Study 31274187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRA and LTA
Number of subjects: 77
Study 30169201 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (3 times per week for 6 months, 72 sessions total, intensity from 50% to 70% of one repetition maximum)
Number of subjects: 60
Study 30169201 — intervention group
Group type: COMPARATOR
Intervention: Sham training (negligible non‐progressed intensity)
Number of subjects: 60
Study 30169201 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Number of subjects: 60
Study 30169201 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 60
Study 25756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional fitness and cognitive training for 12 weeks
Number of subjects: 34
Study 25756064 — intervention group
Group type: COMPARATOR
Intervention: No training program (Control)
Number of subjects: 34
Study 25432118 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (group LP)
Number of subjects: 60
Study 25432118 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (group OP)
Number of subjects: 60
Study 21859051 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin nightly for 30 days
Number of subjects: 61
Study 21859051 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 30 days
Number of subjects: 61
Study 19008077 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g twice daily (n=24)
Number of subjects: 47
Study 19008077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 47
Study 17879994 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study 17879994 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor components of olive oil
Number of subjects: 0
Study 15377131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (group Ia)
Number of subjects: 144
Study 15377131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group Ib)
Number of subjects: 144
Study 15377131 — intervention group
Group type: COMPARATOR
Intervention: Ventricular rate control (diltiazem, group II)
Number of subjects: 144
Study 15377131 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of group I vs group II
Number of subjects: 144
Study 11248761 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5mg/daily)
Number of subjects: 58
Study 11248761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30mg/daily)
Number of subjects: 58
Study 9492126 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate
Number of subjects: 124
Study 9492126 — intervention group
Group type: COMPARATOR
Intervention: Standard wound closure techniques
Number of subjects: 124
Study 8046180 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop plus foodservice manual
Number of subjects: 46
Study 8046180 — intervention group
Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 46
Study 8046180 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study 2606287 — intervention group
Group type: EXPERIMENTAL
Intervention: Synonyms
Number of subjects: 3
Study 2606287 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraphrases
Number of subjects: 3
Study 2606287 — intervention group
Group type: COMPARATOR
Intervention: Repetitions
Number of subjects: 3
Study 30206690 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 µg/kg/min)
Number of subjects: 142
Study 30206690 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 142
Study 26795935 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa program (intervention)
Number of subjects: 7010
Study 26795935 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7010
Study 25601592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 150
Study 23418465 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of ADVAX (DNA vaccine) + 2 doses of TBC-M4 (recombinant MVA) in Group A
Number of subjects: 32
Study 23418465 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of TBC-M4 (recombinant MVA) in Group B
Number of subjects: 32
Study 23418465 — intervention group
Group type: COMPARATOR
Intervention: Placebo in both groups
Number of subjects: 32
Study 20173188 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated distribution of locations
Number of subjects: 0
Study 20173188 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated background texture
Number of subjects: 0
Study 18164280 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning condition (study of 160 word pairs)
Number of subjects: 0
Study 18164280 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-learning perceptual priming task)
Number of subjects: 0
Study 16083539 — intervention group
Group type: EXPERIMENTAL
Intervention: Econopred Plus 1% (EPP)
Number of subjects: 0
Study 16083539 — intervention group
Group type: COMPARATOR
Intervention: Pred Fortedagger 1% (PF)
Number of subjects: 0
Study 12117879 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (2 mg folic acid per day for three months)
Number of subjects: 11
Study 12117879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 11
Study 10513037 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction/supervision/reinforcement/stimulation for six months
Number of subjects: 296
Study 10513037 — intervention group
Group type: COMPARATOR
Intervention: Instruction/supervision only
Number of subjects: 296
Study 7750598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 30
Study 7750598 — intervention group
Group type: COMPARATOR
Intervention: Natural intercourse
Number of subjects: 30
Study 7750598 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 30
Study 1983112 — intervention group
Group type: COMPARATOR
Intervention: nizatidine (300 mg h.s.)
Number of subjects: 20
Study 1983112 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine (40 mg h.s.)
Number of subjects: 20
Study 7016432 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of 15-methyl-PGF2 alpha methyl ester in a vaginal suppository
Number of subjects: 1001
Study 7016432 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 1001
Study 31117815 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH-HF intervention (home-based, health-professional-facilitated, self-management programme) over 12 weeks
Number of subjects: 97
Study 31117815 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 97
Study 27866454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed continuation maintenance therapy
Number of subjects: 87
Study 25412116 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-antitrypsin deficiency (AATD)
Number of subjects: 10
Study 25412116 — intervention group
Group type: EXPERIMENTAL
Intervention: usual COPD
Number of subjects: 10
Study 25412116 — intervention group
Group type: EXPERIMENTAL
Intervention: AATD and usual COPD
Number of subjects: 10
Study 25412116 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 10
Study 24140442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release oxycodone-naloxone (5.0 mg oxycodone, 2.5 mg naloxone, twice per day, up-titrated to a maximum of 40 mg oxycodone, 20 mg naloxone, twice per day)
Number of subjects: 276
Study 24140442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 24140442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release oxycodone-naloxone (during open-label extension phase)
Number of subjects: 276
Study 24140442 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release oxycodone-naloxone
Number of subjects: 276
Study 21873926 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal refractive therapy
Number of subjects: 30
Study 19188184 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 synthetic long peptide (p53-SLP) vaccine, administered twice
Number of subjects: 10
Study 17595592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with estradiol patches (50 microg/24 h) and oral medroxyprogesterone acetate (2.5 mg/d)
Number of subjects: 40
Study 17595592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 40
Study 17595592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15188978 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 26
Study 15188978 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 11932073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 40
Study 11932073 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 9672273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day for 5 years
Number of subjects: 5408
Study 9672273 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 years
Number of subjects: 5408
Study 9672273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen among women using hormone-replacement therapy
Number of subjects: 5408
Study 9672273 — intervention group
Group type: COMPARATOR
Intervention: Placebo among women using hormone-replacement therapy
Number of subjects: 5408
Study 9672273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 5408
Study 9672273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study 8023775 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (15 mg/kg)
Number of subjects: 31
Study 3076382 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) (radiation dose, 20-30 Gy)
Number of subjects: 20
Study 3076382 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA)
Number of subjects: 20
Study 29031641 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised AT conditioning protocol (10×25s plantarflexion contractions at 50% MVIC)
Number of subjects: 10
Study 25675393 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 10
Study 23003916 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified perforated bovine collagen membranes (MPM)
Number of subjects: 20
Study 23003916 — intervention group
Group type: COMPARATOR
Intervention: Occlusive bovine collagen membranes (OM)
Number of subjects: 20